OptimizeRx Q4 EPS Jumps 119% to $0.51, Revenues Beat at $32.24M
OptimizeRx posted Q4 adjusted EPS of $0.51, beating the $0.23 estimate by 119% and generating revenues of $32.24 million, a 2.1% surprise. Shares have fallen 35.8% year-to-date while consensus forecasts project $0.08 EPS on $23.76 million revenue next quarter and $0.91 on $122.83 million for the fiscal year.
1. Q4 Financial Results
In the quarter ended December 2025, OptimizeRx delivered adjusted earnings of $0.51 per share, exceeding the $0.23 consensus by 119%, and reported revenues of $32.24 million, a 2.1% beat on estimates and essentially flat versus $32.32 million a year earlier.
2. Share Performance and Industry Context
OptimizeRx shares have declined 35.8% since the start of the year, underperforming the broader market, while the Computer-Software industry sits in the top 35% of peers by performance, reflecting mixed sentiment around growth prospects.
3. Forward Estimates and Outlook
Analysts forecast $0.08 EPS on $23.76 million revenue for Q1 and $0.91 EPS on $122.83 million revenue for the fiscal year, with management commentary on the upcoming earnings call expected to drive estimate revisions and stock direction.